Evicenter
P&T meetings

Tirabrutinib

Primary central nervous system lymphoma

Regulatory submission
NDA submitted December 2025
Last updated
72 sources

Clinical evidence

Taiwan multicenter salvage-treatment cohort

9 evidence topics · 1 source

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using overall response rate as an effectiveness endpoint
Endpoint rationale

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)
Analysis population sizes
MeasureQuoted value
Safety population“18”
Effectiveness population“17”
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

This retrospective cohort included 18 participants in the safety population and 17 in the effectiveness population. One participant contributed only to the safety analysis. The response estimate and infection proportion therefore have different denominators, and neither establishes comparative benefit or harm against another treatment.